RCT | Intravenous iron did not significantly reduce hospital admissions in patients with heart failure and iron deficiency.

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial – The Lancet

Commentaries:

Effectiveness of Intravenous Iron Treatment Versus Standard Care in Patients With Heart Failure and Iron Deficiency – IRONMAN – American College of Cardiology

IRONMAN Misses but Lends Support to IV Iron Repletion in HF – TCTMD